Position in LLY
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$8,385,215
+$4,505,626 QoQ
Shares Held
6,991
+65.7% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#1,363
of 4,632 holders
Holding Since
Mar 2022
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026XTX Topco Ltd holds $46,000,026 across 13 Drug Manufacturers - General names. LLY ranks #3 (18.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
834,735 | $20,100,418 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
68,150 | $8,610,071 | |
| 3 | LLY |
ELI LILLY & Co
This page
|
6,991 | $8,385,215 | |
| 4 | NVO |
Novo Nordisk A S
|
48,420 | $2,321,254 | |
| 5 | GSK |
GSK plc
|
35,304 | $1,850,635 | |
| 6 | NVS |
Novartis AG
|
11,248 | $1,762,786 | |
| 7 | JNJ |
Johnson & Johnson
|
5,135 | $1,304,135 | |
| 8 | BIIB |
Biogen Inc.
|
3,239 | $699,818 |
All Filings in LLY
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,385,215 | 6,991 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $3,879,589 | 4,218 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $1,023,095 | 952 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $2,948,232 | 3,864 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $9,026,957 | 11,580 | Shares | Defined | 2025-08-12 | |
| 2024-06-30 | $545,944 | 603 | Shares | Defined | 2024-08-12 | |
| 2023-12-31 | $737,976 | 1,266 | Shares | Defined | 2024-02-13 | |
| 2023-09-30 | $3,346,857 | 6,231 | Shares | Defined | 2023-11-13 | |
| 2022-12-31 | $903,990 | 2,471 | Shares | Defined | 2023-02-14 | |
| 2022-03-31 | $241,696 | 844 | Shares | Defined | 2022-05-13 | |
| No filing history on record for this holder in this stock. | ||||||